CORE EARNINGS PER SHARE FORECAST: Fourth-quarter core earnings per share is expected to fall to 20.6 pounds from 28.9 pounds the year earlier, according to Visible Alpha. Shares in GSK are 3.6% up ...

Exploring Analgesics as a Key Painkiller Types & Their Role in Pain ReliefUnited States, New York, Feb. 04, 2025 (GLOBE ...

Northern Ireland science and Technology hub, Catalyst has announced the appointment of Dr Rob Grundy as its new director of ...

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

A jab given to patients to battle RSV through the NHS could potentially cause a disabling condition known as Guillain-Barré ...

Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

The 30th Nigerian Economic Summit (#NES30) was held in Abuja on October 14, 2024. At that summit, the Vice President of the ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

Coherus BioSciences, Inc.’s CHRS share price has dipped by 12.59%, which has investors questioning if this is right time to ...

Dr. Blackman brings his singular experience as co-founder of Day One Biopharmaceuticals and a physician-scientist in pediatric neuro-oncology to the PBTF’s pediatric brain tumor communityBOSTON, Jan.

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.